View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 13, 2019

Boehringer and IBM to explore blockchain technology in clinical trials

Canadian subsidiaries of Boehringer Ingelheim and IBM have partnered to employ blockchain technology for improving the quality and record keeping in clinical trials.

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

The companies noted that their alliance would be the first to explore the technology in a clinical trial in the country.

According to regulatory authorities, processes used to maintain the quality of trials are commonly found to be inadequate, and the trial records are mostly erroneous or incomplete.

These types of discrepancies could be a risk for patient safety and trial interpretability, the companies added.

Boehringer and IBM intend to assess the use of blockchain as a decentralised framework in clinical trials to allow data integrity, provenance, transparency, patient empowerment and automation of processes.

The result is expected to improve trial quality and patient safety at a lower cost.

Boehringer Ingelheim (Canada) Medical and Regulatory Affairs vice-president Uli Brödl said: “The clinical trial ecosystem is highly complex as it involves different stakeholders, resulting in limited trust, transparency and process inefficiencies without true patient empowerment.

“Patients are at the heart of everything we do, so we are looking into novel solutions to improve patient safety and empowerment.”

Under the alliance, IBM Canada will deliver the core blockchain technologies that provide patient consent, secure health data exchange and patient engagement.

IBM Canada Services general manager Claude Guay said: “We’ve been using blockchain in other industries, and we are now investigating how we can use this technology to give Canadian patients the same level of security and trust when it comes to their personal health information.”

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena